Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
51 hedge funds and large institutions have $30.2M invested in Infinity Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 16 reducing their positions, and 7 closing their positions.
2.48% less ownership
Funds ownership: 53.92% → 51.45% (-2.5%)
7% less funds holding
Funds holding: 55 → 51 (-4)
45% less capital invested
Capital invested by funds: $55.2M → $30.2M (-$25M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
63% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 16
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$162K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$26.3K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$14.6K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$13.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
-$900K |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$728K |
| 3 |
JP Morgan Chase
New York
|
-$299K |
| 4 |
AC
Athanor Capital
New York
|
-$116K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$76K |
INFI Hedge Fund Activity: Q3 2019 in Review
51 of the 4,575 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q3 2019, worth a combined $30.2M — down 45% from $55.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of INFI and 3 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $162K. The largest seller was First Eagle Investment Management, exiting entirely with an estimated $900K sold.
- 51 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q3 2019, down from 55 in Q2 2019.
- Funds reported $30.2M of Infinity Pharmaceuticals, Inc. stock for Q3 2019, down 45% quarter-over-quarter.
- 3 funds opened new Infinity Pharmaceuticals, Inc. positions in Q3 2019 and 7 closed out, a net change of -4 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q3 2019 was Renaissance Technologies, an estimated $162K added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q3 2019 was First Eagle Investment Management, an estimated $900K sold.
Based on aggregated 13F filings for Q3 2019.